Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00940095




Registration number
NCT00940095
Ethics application status
Date submitted
13/07/2009
Date registered
15/07/2009
Date last updated
9/07/2018

Titles & IDs
Public title
Clazosentan in Aneurysmal Subarachnoid Hemorrhage
Scientific title
A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Endovascular Coiling.
Secondary ID [1] 0 0
AC-054-302
Universal Trial Number (UTN)
Trial acronym
CONSCIOUS-3
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Aneurysmal Subarachnoid Hemorrhage 0 0
Condition category
Condition code
Neurological 0 0 0 0
Other neurological disorders
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Clazosentan 5 m/h
Treatment: Drugs - Clazosentan 15 mg/h
Treatment: Drugs - Placebo

Experimental: Clazosentan 5 mg/h - Continuous intravenous infusion of clazosentan (5 mg/h) started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14

Experimental: Clazosentan 15 mg/h - Continuous intravenous infusion of clazosentan (15 mg/h) started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14

Placebo Comparator: Placebo - Continuous intravenous infusion of placebo matching clazosentan started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14


Treatment: Drugs: Clazosentan 5 m/h
Continuous intravenous infusion of clazosentan (5 mg/h)

Treatment: Drugs: Clazosentan 15 mg/h
Continuous intravenous infusion of clazosentan clazosentan (15 mg/h)

Treatment: Drugs: Placebo
Continuous intravenous infusion of placebo-matching clazosentan
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Cerebral vasospasm-related morbidity and mortality of all-causes as defined by the protocol
Timepoint [1] 0 0
Within 6 weeks post-aSAH
Secondary outcome [1] 0 0
Glasgow Outcome Scale Extended (GOSE) at Week 12 post-aSAH, dichotomized into good (score > 4) and poor (score = 4) outcome.
Timepoint [1] 0 0
Week 12 post-aSAH

Eligibility
Key inclusion criteria
Inclusion Criteria :

1. Males and females aged 18 to 75 years (inclusive).

2. Patients with a ruptured saccular aneurysm, confirmed by angiography (digital
subtraction angiography [DSA] or computed tomography angiography [CTA], investigator's
assessment), and which has been successfully* secured by endovascular coiling. The
time of aneurysm rupture must be known or possible to estimate with a reasonable
degree of certainty.

3. World Federation of Neurological Surgeons (WFNS) grade I-IV measured prior to the
endovascular coiling procedure, and which does not worsen to grade V post-procedure
(based on regular Glasgow Coma Scale [GCS])

4. Patients with any thick clot (short axis > or = 4 mm) on baseline CT scan
(investigator's assessment).

5. Women of childbearing potential must have a negative serum pregnancy test and must use
a reliable method of contraception during the 12 weeks following study drug
discontinuation.

6. Written informed consent to participate in the study must be obtained from the patient
or a legal representative prior to initiation of any study-mandated procedure and
randomization.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria :

1. Subarachnoid hemorrhage (SAH) due to causes other than saccular aneurysm.

2. Giant aneurysms (height or width > or = 25 mm).

3. Intraventricular or intracerebral blood, in absence of subarachnoid blood, or or with
only a thin clot (short axis < 4 mm)

4. Cerebral vasospasm on angiography (investigator's assessment) prior to endovascular
coiling (intraprocedural cerebral vasospasm is not an exclusion criterion).

5. A major complication during the endovascular coiling procedure, such as massive
intracranial bleeding, intracranial thromboembolism, coil migration, aneurysm
perforation or rupture, arterial dissection, major arterial occlusion, a large
territorial cerebral infarct defined as involving > 1/3 of a vascular territory, or a
new major neurological deficit post-procedure (e.g., hemiplegia or aphasia lasting >
or = 12 hours post-aneurysm coiling)*.

6. Current ruptured aneurysm previously secured (successfully or not) by clipping.

7. Coiling material used, which has not been approved by local health authorities.

8. Use of liquid embolism aneurysmal treatment or flow diverting device.

9. Several aneurysms among which the ruptured one cannot be identified with certainty and
which are not all secured during the coiling procedure.

10. No end-of-procedure DSA.

11. Another securing procedure planned for any aneurysm between randomization and Week 12
post-aSAH.

12. Study drug start >56 hours after the aneurysm rupture.

13. Known, at time of screening, that certain follow-up, or protocol-mandated imaging
assessments will not be feasible.

14. Hypotension (systolic blood pressure < or = 90 mmHg) refractory to treatment.

15. Aspiration pneumonia.

16. Pulmonary edema or severe cardiac failure requiring inotropic support at time of
randomization.

17. Any severe or unstable concomitant condition or disease (e.g., known significant
neurological deficit, cancer, hematological, coronary disease, psychiatric disorder),
which would affect assessment of the safety or efficacy of the study drug
(investigator's opinion).

18. Significant kidney disease defined by plasma creatinine > or = 2.5 mg/dL (221
micromol/l) and/or liver disease defined by total bilirubin > 2-fold Upper Limit of
Normal as measured at local laboratory, and/or known diagnosis or clinical suspicion
of liver cirrhosis.

19. Infusion of i.v. nimodipine or i.v. nicardipine must have these drugs discontinued at
least 4 hours prior to initiation of study treatment.

20. Infusion of i.v. fasudil within 24-hour period preceding planned start of study drug
initiation.

21. Start of statins less than 2 weeks prior to admission must have them discontinued
prior to study drug initiation.

22. Infusion of cyclosporin A or other calcineurin inhibitors (e.g., tacrolimus), or
patients for whom it is known at the time of randomization that these medications will
be started during the study drug infusion period.

23. Intake of an investigational product including investigational coil material within 28
days prior to randomization or those who have already participated in current study or
CONSCIOUS-2 (AC-054-301).

24. Unlikely event to comply with protocol (e.g., unable to return for follow-up visits).

25. Known hypersensitivity to other endothelin receptor antagonists.26.current alcohol or
drug abuse/dependence.

- "Large territorial infarct" refers to infarcts detected during the endovascular
coiling procedure or immediately post-procedure (i.e., CT performed for suspicion
of cerebral infarct or other complication). This does not imply having to wait
24-48 hours post-procedure to perform the protocol-mandated CT scan in order to
randomize a patient. Evaluation for a new major neurological deficit
post-procedure implies reversal of sedation and performance of a GCS examination
(verbal scores in intubated patients may be extrapolated from the eye-opening and
motor scores using predefined values). If a new major neurological deficit does
not improve within 12 hours after the coiling procedure, the patient cannot be
included.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/07/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/01/2011
Sample size
Target
Accrual to date
Final
577
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 0 0
Gold Coast Hospital - Southport
Recruitment hospital [2] 0 0
Royal Brisbane & Women's Hosptal - Brisbane
Recruitment hospital [3] 0 0
Royal Prince Alfred Hosptial - Camperdown
Recruitment hospital [4] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [5] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 0 0
4215 - Southport
Recruitment postcode(s) [2] 0 0
QLD 4029 - Brisbane
Recruitment postcode(s) [3] 0 0
NSW 2050 - Camperdown
Recruitment postcode(s) [4] 0 0
VIC 3168 - Clayton
Recruitment postcode(s) [5] 0 0
QLD 4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Minnesota
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Ohio
Country [14] 0 0
United States of America
State/province [14] 0 0
Oklahoma
Country [15] 0 0
United States of America
State/province [15] 0 0
Oregon
Country [16] 0 0
United States of America
State/province [16] 0 0
Pennsylvania
Country [17] 0 0
United States of America
State/province [17] 0 0
South Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Virginia
Country [20] 0 0
Argentina
State/province [20] 0 0
Buenos Aires
Country [21] 0 0
Austria
State/province [21] 0 0
Graz
Country [22] 0 0
Austria
State/province [22] 0 0
Innsbruck
Country [23] 0 0
Austria
State/province [23] 0 0
Salzburg
Country [24] 0 0
Austria
State/province [24] 0 0
Vienna
Country [25] 0 0
Belgium
State/province [25] 0 0
Antwerp
Country [26] 0 0
Belgium
State/province [26] 0 0
Brussels
Country [27] 0 0
Belgium
State/province [27] 0 0
Gent
Country [28] 0 0
Belgium
State/province [28] 0 0
Leuven
Country [29] 0 0
Brazil
State/province [29] 0 0
Belo Horizonte
Country [30] 0 0
Brazil
State/province [30] 0 0
Curitiba
Country [31] 0 0
Brazil
State/province [31] 0 0
Joinville
Country [32] 0 0
Brazil
State/province [32] 0 0
Niteroí
Country [33] 0 0
Brazil
State/province [33] 0 0
Porto Alegre
Country [34] 0 0
Brazil
State/province [34] 0 0
Sao Paulo
Country [35] 0 0
Brazil
State/province [35] 0 0
Sobral
Country [36] 0 0
Canada
State/province [36] 0 0
Alberta
Country [37] 0 0
Canada
State/province [37] 0 0
British Columbia
Country [38] 0 0
Canada
State/province [38] 0 0
Nova Scotia
Country [39] 0 0
Canada
State/province [39] 0 0
Ontario
Country [40] 0 0
Canada
State/province [40] 0 0
Quebec
Country [41] 0 0
Canada
State/province [41] 0 0
Saskatchewan
Country [42] 0 0
Chile
State/province [42] 0 0
Concepcion
Country [43] 0 0
Chile
State/province [43] 0 0
Santiago
Country [44] 0 0
Chile
State/province [44] 0 0
Valparaiso
Country [45] 0 0
Czechia
State/province [45] 0 0
Brno
Country [46] 0 0
Czechia
State/province [46] 0 0
Ceske Budejovice
Country [47] 0 0
Czechia
State/province [47] 0 0
Ostrava
Country [48] 0 0
Czechia
State/province [48] 0 0
Praha
Country [49] 0 0
Czechia
State/province [49] 0 0
Usti nad Labem
Country [50] 0 0
Denmark
State/province [50] 0 0
Copenhagen
Country [51] 0 0
Denmark
State/province [51] 0 0
Glostrup
Country [52] 0 0
Denmark
State/province [52] 0 0
Odense
Country [53] 0 0
Finland
State/province [53] 0 0
Helsinki
Country [54] 0 0
Finland
State/province [54] 0 0
Tampere
Country [55] 0 0
France
State/province [55] 0 0
Angers Cedex 9
Country [56] 0 0
France
State/province [56] 0 0
Bordeaux cedex
Country [57] 0 0
France
State/province [57] 0 0
Bron
Country [58] 0 0
France
State/province [58] 0 0
Creteil
Country [59] 0 0
France
State/province [59] 0 0
Dijon
Country [60] 0 0
France
State/province [60] 0 0
Marseille cedex 5
Country [61] 0 0
France
State/province [61] 0 0
Montpellier
Country [62] 0 0
France
State/province [62] 0 0
Nancy
Country [63] 0 0
Germany
State/province [63] 0 0
Augsburg
Country [64] 0 0
Germany
State/province [64] 0 0
Berlin
Country [65] 0 0
Germany
State/province [65] 0 0
Bonn
Country [66] 0 0
Germany
State/province [66] 0 0
Dresden
Country [67] 0 0
Germany
State/province [67] 0 0
Erlangen
Country [68] 0 0
Germany
State/province [68] 0 0
Essen
Country [69] 0 0
Germany
State/province [69] 0 0
Frankfurt
Country [70] 0 0
Germany
State/province [70] 0 0
Freiburg
Country [71] 0 0
Germany
State/province [71] 0 0
Hamburg
Country [72] 0 0
Germany
State/province [72] 0 0
Heidelberg
Country [73] 0 0
Germany
State/province [73] 0 0
Leipzig
Country [74] 0 0
Germany
State/province [74] 0 0
Munich
Country [75] 0 0
Germany
State/province [75] 0 0
Regensburg
Country [76] 0 0
Hong Kong
State/province [76] 0 0
Hong Kong
Country [77] 0 0
Hong Kong
State/province [77] 0 0
Shatin
Country [78] 0 0
Hungary
State/province [78] 0 0
Borsod Abauj-Zemplen
Country [79] 0 0
Hungary
State/province [79] 0 0
Borsod-Abauj-Zemplen
Country [80] 0 0
Hungary
State/province [80] 0 0
Pecs
Country [81] 0 0
India
State/province [81] 0 0
Chandigarh
Country [82] 0 0
India
State/province [82] 0 0
Hyderabad
Country [83] 0 0
India
State/province [83] 0 0
Pune
Country [84] 0 0
Israel
State/province [84] 0 0
Haifa
Country [85] 0 0
Israel
State/province [85] 0 0
Jerusalem
Country [86] 0 0
Israel
State/province [86] 0 0
Tel Hashomer
Country [87] 0 0
Italy
State/province [87] 0 0
Bologna
Country [88] 0 0
Italy
State/province [88] 0 0
Firenze
Country [89] 0 0
Italy
State/province [89] 0 0
Rome
Country [90] 0 0
Italy
State/province [90] 0 0
Verona
Country [91] 0 0
Mexico
State/province [91] 0 0
Mexico City
Country [92] 0 0
Mexico
State/province [92] 0 0
Monterrey
Country [93] 0 0
Netherlands
State/province [93] 0 0
Tilburg
Country [94] 0 0
Norway
State/province [94] 0 0
Bergen
Country [95] 0 0
Norway
State/province [95] 0 0
Oslo
Country [96] 0 0
Norway
State/province [96] 0 0
Tromso
Country [97] 0 0
Poland
State/province [97] 0 0
Gdansk
Country [98] 0 0
Poland
State/province [98] 0 0
Warszawa
Country [99] 0 0
Singapore
State/province [99] 0 0
Singapore
Country [100] 0 0
Slovenia
State/province [100] 0 0
Ljubljana
Country [101] 0 0
Slovenia
State/province [101] 0 0
Maribor
Country [102] 0 0
Spain
State/province [102] 0 0
Barcelona
Country [103] 0 0
Spain
State/province [103] 0 0
Granada
Country [104] 0 0
Spain
State/province [104] 0 0
Madrid
Country [105] 0 0
Spain
State/province [105] 0 0
Palma de Mallorca
Country [106] 0 0
Sweden
State/province [106] 0 0
Goteborg
Country [107] 0 0
Sweden
State/province [107] 0 0
Linkoping
Country [108] 0 0
Sweden
State/province [108] 0 0
Lund
Country [109] 0 0
Switzerland
State/province [109] 0 0
Aarau
Country [110] 0 0
Switzerland
State/province [110] 0 0
Bern
Country [111] 0 0
Switzerland
State/province [111] 0 0
Geneva
Country [112] 0 0
Switzerland
State/province [112] 0 0
Zurich
Country [113] 0 0
Taiwan
State/province [113] 0 0
Taipei

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Idorsia Pharmaceuticals Ltd.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The aim of this study is to demonstrate that clazosentan, administered as a continuous
intravenous infusion at either 5 mg/h or 15 mg/h until Day 14 post aneurysmal subarachnoid
hemorrhage (aSAH), reduces the incidence of cerebral vasospasm-related morbidity and
all-cause mortality within 6 weeks post-aSAH treated by endovascular coiling.

The primary endpoint of the study is the occurrence of cerebral vasospasm-related morbidity,
and mortality of all-causes within 6 weeks post-aSAH, defined by at least one of the
following:

1. Death (all causes).

2. New cerebral infarct(s) due to cerebral vasospasm as either the primary or relevant
contributing cause, or not adjudicated to be entirely due to causes other than
vasospasm.

3. Delayed ischemic neurological deficit (DIND) due to cerebral vasospasm as either the
primary or relevant contributing cause, or not adjudicated to be entirely due to causes
other than vasospasm.

4. Administration of a valid rescue therapy in the presence of confirmed cerebral vasospasm
on angiography (DSA or CTA).

An independent Critical Events Committee (CEC) will adjudicate whether or not patients meet
the primary endpoint and its individual morbidity components.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00940095
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Sebastien Roux, MD
Address 0 0
Actelion
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00940095